Lucid Diagnostics (LUCD) EBITDA (2020 - 2026)

Lucid Diagnostics (LUCD) has reported EBITDA for 7 consecutive years, with -$12.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 12.45% year-over-year to -$12.8 million; the trailing twelve-month figure through Jun 2026 stood at -$50.7 million (down 5.73% YoY), and the FY2025 full-year result was -$49.6 million, down 7.79% from the prior year.
• EBITDA retreated to -$12.8 million in Q2 2026 per LUCD's latest filing, from -$12.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$10.8 million in Q1 2024 and bottomed at -$15.0 million in Q4 2022.
• Historically, EBITDA has averaged -$12.5 million across 5 years, with a median of -$12.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: EBITDA plunged 235.92% in 2022, then rose 24.62% in 2024.
• Over 5 years, EBITDA stood at -$15.0 million in 2022, then climbed by 23.52% to -$11.5 million in 2023, then retreated by 8.05% to -$12.4 million in 2024, then dropped by 13.22% to -$14.0 million in 2025, then increased by 8.64% to -$12.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$12.8 million, -$12.1 million, and -$14.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.